Laverty Daniel J, Averill April M, Doublié Sylvie, Greenberg Marc M
Department of Chemistry, Johns Hopkins University , 3400 N. Charles St., Baltimore, Maryland 21218, United States.
Department of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, The University of Vermont , 95 Carrigan Drive, Burlington, Vermont 05405, United States.
ACS Chem Biol. 2017 Jun 16;12(6):1584-1592. doi: 10.1021/acschembio.7b00211. Epub 2017 May 1.
DNA polymerase θ (Pol θ) is implicated in various cellular processes including double-strand break repair and apurinic/apyrimidinic site bypass. Because Pol θ expression correlates with poor cancer prognosis, the ability of Pol θ to bypass the C4'-oxidized abasic site (C4-AP) and 2-deoxyribonolactone (L), which are generated by cytotoxic agents, is of interest. Translesion synthesis and subsequent extension by Pol θ past C4-AP or L and an abasic site (AP) or its tetrahydrofuran analogue (F) was examined. Pol θ conducts translesion synthesis on templates containing AP and F with similar efficiencies and follows the "A-rule," inserting nucleotides in the order A > G > T. Translesion synthesis on templates containing C4-AP and L is less efficient than AP and F, and the preference for A insertion is reduced for L and absent for C4-AP. Extension past all abasic lesions (AP, F, C4-AP, and L) was significantly less efficient than translesion synthesis and yielded deletions caused by the base one or two nucleotides downstream from the lesion being used as a template, with the latter being favored. These results suggest that bypass of abasic lesions by Pol θ is highly mutagenic.
DNA聚合酶θ(Pol θ)参与多种细胞过程,包括双链断裂修复和无嘌呤/无嘧啶位点的跨损伤合成。由于Pol θ的表达与癌症预后不良相关,因此Pol θ绕过由细胞毒性剂产生的C4'-氧化无碱基位点(C4-AP)和2-脱氧核糖内酯(L)的能力备受关注。研究了Pol θ在C4-AP或L以及无碱基位点(AP)或其四氢呋喃类似物(F)之后进行跨损伤合成及后续延伸的情况。Pol θ在含有AP和F的模板上进行跨损伤合成的效率相似,并遵循“A规则”,即按A>G>T的顺序插入核苷酸。在含有C4-AP和L的模板上进行跨损伤合成的效率低于含有AP和F的模板,并且对于L,A插入的偏好降低,对于C4-AP则不存在A插入偏好。越过所有无碱基损伤(AP、F、C4-AP和L)的延伸效率明显低于跨损伤合成,并产生了由损伤下游一两个核苷酸作为模板导致的缺失,其中以后者更为常见。这些结果表明,Pol θ绕过无碱基损伤具有高度致突变性。